Ipamorelin for Chronic Tendinopathy: A Structured Clinical Protocol

Why Growth Hormone Signaling Matters for Tendons

Chronic tendinopathy is not a simple inflammatory condition. Histological studies show failed healing characterized by disorganized collagen, neovascularization, and a paucity of inflammatory cells, a process researchers now call "failed tendon repair" rather than classic tendinitis [1]. Because growth hormone (GH) and its downstream mediator IGF-1 directly stimulate tenocyte proliferation and type I collagen synthesis, interventions that raise GH pulsatility are biologically plausible for this condition [2].

The Role of IGF-1 in Tendon Repair

IGF-1 receptors are expressed on tenocytes throughout the tendon proper. When IGF-1 binds these receptors, it activates the PI3K/Akt pathway, which increases collagen gene transcription and reduces apoptosis of resident tenocytes [2]. Animal studies published in peer-reviewed journals confirm that local IGF-1 application accelerates tendon-to-bone healing after surgical repair [3]. Systemic elevation of IGF-1 through GH secretagogues may replicate part of this effect without direct injection into fragile tendon tissue.

Why Ipamorelin Specifically

Ipamorelin is a synthetic pentapeptide that binds the ghrelin receptor (GHSR-1a) with high selectivity. Unlike older secretagogues such as GHRP-2 or GHRP-6, ipamorelin does not meaningfully raise cortisol or prolactin at therapeutic doses [4]. That selectivity matters clinically because cortisol elevation can suppress collagen synthesis, the very outcome the protocol is trying to promote. A rat study in the journal Regulatory Peptides found that GHRP-6 (a structurally similar secretagogue) significantly improved collagen organization and tensile strength in surgically transected tendons compared with saline controls (P<0.01) [5]. Ipamorelin's cleaner receptor profile makes it the preferred secretagogue in current practitioner protocols, though direct head-to-head tendon data comparing ipamorelin to GHRP-6 do not yet exist in humans.

Understanding Chronic Tendinopathy: The Clinical Context

Recalcitrant tendinopathy affects a significant portion of recreational and competitive athletes. Achilles tendinopathy alone has an estimated lifetime prevalence of approximately 24% in formerly active runners [6]. Standard-of-care management, eccentric loading programs, shockwave therapy, and platelet-rich plasma (PRP) injections, fails to produce satisfactory outcomes in a meaningful subset of patients [7].

Where Conventional Treatment Falls Short

The 2022 British Journal of Sports Medicine clinical practice guide for mid-portion Achilles tendinopathy endorses a progressive tendon loading program as first-line treatment, noting that PRP injection showed no significant benefit over placebo saline injection in the largest randomized trial to date (ISRCTN, N=240) [7]. For patients who complete a structured 12-week eccentric loading program and remain symptomatic, no well-validated pharmacological options exist within conventional medicine. That gap is precisely where investigational peptide protocols are being explored.

Pathological Subtypes Relevant to Ipamorelin Use

The three tendon sites most often discussed in practitioner reports are:

• Achilles tendinopathy (mid-portion): affects the tendon 2 to 6 cm proximal to the calcaneal insertion; characterized by fusiform swelling and morning stiffness
• Patellar tendinopathy: involves the proximal pole attachment; common in jumping athletes and often graded with the Victorian Institute of Sport Assessment (VISA-P) score
• Rotator cuff tendinopathy: typically involves the supraspinatus at its insertion on the greater tuberosity; frequently co-exists with subacromial impingement

Each of these conditions shares the same histopathological failure-of-healing pattern [1], which is why a single mechanistic intervention like IGF-1 elevation may apply across all three sites.

Proposed Ipamorelin Protocol for Chronic Tendinopathy

The following protocol synthesizes available preclinical data, GH physiology research, and structured practitioner experience. Every recommendation is graded by evidence level. No human RCT of ipamorelin in tendinopathy has been published as of this writing.

Dosing and Administration

Standard starting dose: 200 mcg subcutaneous injection, administered 2 times daily.

Titration: If fasting IGF-1 remains below age- and sex-adjusted reference range at week 4 and the patient tolerates the peptide without adverse effects, the dose may be increased to 300 mcg per injection. Some practitioners use three daily injections (morning, post-workout, and pre-sleep); the pre-sleep injection is timed to coincide with natural somatotroph pulse activity during early slow-wave sleep [8].

Injection sites are rotated across the periumbilical abdomen, lateral thigh, or deltoid subcutaneous fat. Needle length of 29 to 31 gauge, 5/16 inch is appropriate for most patients. Ipamorelin is supplied as a lyophilized powder reconstituted with bacteriostatic water; standard reconstitution yields a concentration of 1 mg/mL, making 200 mcg equal to 0.2 mL per injection.

Evidence level for this dose range: Observational practitioner experience, supported by GH pharmacokinetic data from healthy-volunteer studies showing peak GH elevation 30 to 60 minutes after subcutaneous GHRP administration [4].

Injection Timing and Nutrient Considerations

Ipamorelin should be administered in a fasted state or at least 90 minutes after a meal containing carbohydrates or fat. Elevated glucose and free fatty acids blunt somatotroph responsiveness to secretagogue stimulation, reducing the GH pulse amplitude by an estimated 30 to 50% in published pharmacodynamic studies [8]. Protein intake does not appear to blunt the GH response to the same degree.

Patients taking ipamorelin pre-sleep should avoid eating within 2 hours of the injection. This restriction aligns with the overall fasting requirements for accurate IGF-1 assay collection (see Monitoring section).

Cycle Length

A minimum 12-week cycle is recommended for chronic tendon pathology. Tendon collagen turns over slowly; half-life of tendon collagen in adult humans has been estimated at several years using carbon-14 dating techniques, though newly synthesized collagen incorporates within weeks [9]. Practitioner experience suggests that meaningful symptomatic improvement is rarely reported before week 8, and structural improvements observable on diagnostic ultrasound may lag clinical improvement by 4 to 6 weeks.

A 16-week cycle is preferred when baseline VISA scores (VISA-A for Achilles, VISA-P for patellar) fall below 40 out of 100, indicating more severe functional limitation.

After completing a full cycle, a 4 to 8 week off-period is commonly used before reassessment, though no data formally define an optimal rest period for this indication.

Combining Ipamorelin With Established Tendon Therapies

Ipamorelin is not a stand-alone treatment. The most rational protocol pairs it with progressive mechanical loading, which remains the only intervention with strong RCT evidence in chronic tendinopathy [7].

Loading Programs During the Ipamorelin Cycle

A Heavy Slow Resistance (HSR) protocol, 3 sets of 15 repetitions progressing to 3 sets of 6 repetitions at high load over 12 weeks, produced outcomes equivalent to eccentric training in mid-portion Achilles tendinopathy at 12 months in a Danish RCT (N=58, P=0.88 for VISA-A score difference) [10]. Both modalities are appropriate during ipamorelin use. Mechanical loading signals tenocytes to upregulate collagen synthesis through mechanotransduction pathways that are potentiated by IGF-1, creating a plausible additive effect [2].

Shockwave Therapy as an Adjunct

Extracorporeal shockwave therapy (ESWT) delivered at 2,000 impulses per session, 0.25 mJ/mm² energy flux density, once weekly for 3 sessions, reduced pain scores significantly in chronic calcific rotator cuff tendinopathy in a Cochrane-included trial [11]. Running ESWT sessions during weeks 4 to 6 of an ipamorelin cycle, when systemic IGF-1 has reached a new steady state, is theoretically advantageous because ESWT upregulates local growth factor receptors [11].

What to Avoid During the Cycle

Non-steroidal anti-inflammatory drugs (NSAIDs) used chronically may impair tendon healing by suppressing prostaglandin-mediated collagen synthesis [1]. Corticosteroid injections into or around the tendon are contraindicated during the cycle; they are associated with increased tendon rupture risk in observational data and antagonize GH-axis anabolism [7].

Monitoring Labs and Safety Parameters

Baseline Labs Before Starting

All patients should have the following drawn before the first injection:

• Fasting IGF-1 (ng/mL), compared against age- and sex-adjusted laboratory reference range
• Fasting glucose (mg/dL)
• HbA1c (%)
• Comprehensive metabolic panel (CMP) to assess hepatic and renal function
• In men over 40: PSA (prostate-specific antigen), because GH-axis stimulation may promote IGF-1-dependent prostate tissue growth

On-Cycle Monitoring

Repeat fasting IGF-1 and fasting glucose at week 8. The target IGF-1 range during ipamorelin use is the upper quartile of the age- and sex-adjusted reference range. Exceeding the upper limit of normal by more than 1.5-fold should prompt dose reduction. Supraphysiologic IGF-1 is associated with increased colorectal and breast cancer risk in epidemiological cohort data [12].

Fasting glucose should remain below 100 mg/dL. Growth hormone is a counter-regulatory hormone that transiently raises blood glucose; this effect is modest at the doses used in this protocol but warrants monitoring in patients with pre-diabetes (fasting glucose 100 to 125 mg/dL) [13].

Side Effects to Discuss With Patients

• Water retention: mild peripheral edema occurs in some patients, typically resolving within 2 weeks as the body adjusts to elevated GH pulsatility
• Transient hunger: ghrelin receptor agonism can increase appetite; this is less pronounced with ipamorelin than with GHRP-6 due to ipamorelin's selective binding profile [4]
• Tingling in the extremities: a transient carpal tunnel-like paresthesia reported with GH secretagogues, usually resolving spontaneously
• Injection site reactions: erythema and mild induration at subcutaneous sites, managed by rotation

Ipamorelin is not FDA-approved for any indication. Use in tendinopathy is investigational. Physicians prescribing this peptide operate under off-label prescribing authority [14].

Expected Timeline of Outcomes

Patient expectations should be set clearly before starting the protocol. The following timeline is drawn from practitioner experience and biological plausibility rather than from a controlled trial in this specific population.

• Weeks 1 to 3: Possible improved sleep quality and mild increase in energy; no tendon-specific changes expected
• Weeks 4 to 6: Some patients report reduced morning stiffness; VISA scores may begin to improve modestly
• Weeks 8 to 12: Most practitioners report the window of primary symptomatic improvement; diagnostic ultrasound may begin to show reduced tendon heterogeneity and decreased neovascularity on Doppler imaging
• Weeks 12 to 16: Continued structural remodeling; functional loading capacity typically increases

Objective outcome tracking using validated scores (VISA-A for Achilles, VISA-P for patellar, DASH or Constant-Murley for rotator cuff) at baseline and at weeks 8 and 16 allows meaningful comparison and supports clinical documentation.

Evidence Grading Summary

The table below summarizes the evidence level for each component of this protocol.

| Recommendation | Evidence Level | |---|---| | IGF-1 promotes tenocyte collagen synthesis | Preclinical RCT (animal) [2, 3] | | GHRP-class peptides improve collagen organization in tendons | Animal RCT [5] | | Ipamorelin selectivity for GH vs. Cortisol/prolactin | Human pharmacokinetic study [4] | | Progressive loading as concurrent therapy | Human RCT [10] | | ESWT as adjunct | Cochrane-reviewed RCT [11] | | IGF-1 monitoring for cancer risk | Epidemiological cohort [12] | | Ipamorelin dose 200 to 300 mcg SC 2 to 3x daily | Practitioner observational experience |

No human RCT of ipamorelin specifically in tendinopathy exists. Patients must understand this limitation before consenting to the protocol.

Legal and Regulatory Considerations

Ipamorelin is classified as a research chemical by the FDA and is not approved for human therapeutic use [14]. Compounding pharmacies in the United States have historically provided ipamorelin under Section 503A (patient-specific compounding) and Section 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act. FDA enforcement discretion regarding compounded peptides has shifted in recent years; prescribers should verify current regulatory status with their compounding pharmacy before initiating a prescription.

The World Anti-Doping Agency (WADA) prohibits GH secretagogues including ipamorelin under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) of its Prohibited List. Competitive athletes subject to WADA testing must not use this protocol [15].